We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+59.2%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.69B
AUM Growth
+$748M
Cap. Flow
+$236M
Cap. Flow %
13.95%
Top 10 Hldgs %
59.6%
Holding
45
New
7
Increased
11
Reduced
10
Closed
3

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$96.9M
2
BNR
Burning Rock Biotech
BNR
+$47.4M
3
GBIO
Generation Bio
GBIO
+$35.9M
4
BLFS icon
BioLife Solutions
BLFS
+$32.8M
5
ONC
BeOne Medicines Ltd
ONC
+$24.4M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$19.1M
2
GNMK
GenMark Diagnostics, Inc
GNMK
+$13.9M
3
GILD icon
Gilead Sciences
GILD
+$13.1M
4
SAGE
Sage Therapeutics
SAGE
+$11.1M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 81.83%
2 Materials 1.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVTA
1
DELISTED
Invitae Corporation
NVTA
$274M 16.19%
9,033,943
+5,555,555
+160% +$96.9M
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$121M 7.15%
1,550,000
– –
FATE icon
3
Fate Therapeutics
FATE
$294M
$105M 6.19%
3,050,000
+500,000
+20% +$14.9M
SRPT icon
4
Sarepta Therapeutics
SRPT
$1.63B
$85M 5.03%
530,000
-140,000
-21% -$19.1M
MYOK
5
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$84.1M 4.97%
870,000
-125,000
-13% -$10.4M
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$29.1B
$81.5M 4.82%
550,000
-35,000
-6% -$4.72M
BLFS icon
7
BioLife Solutions
BLFS
$1.56B
$79.3M 4.69%
4,849,524
+2,380,953
+96% +$32.8M
BLUE
8
DELISTED
bluebird bio
BLUE
$67.4M 3.99%
85,306
– –
AGIO icon
9
Agios Pharmaceuticals
AGIO
$1.84B
$57.2M 3.39%
1,070,000
– –
CDXS icon
10
Codexis
CDXS
$157M
$53.5M 3.17%
4,692,732
-381,048
-8% -$4.31M
BNR
11
Burning Rock Biotech
BNR
$95M
$46.7M 2.77%
+173,079
New +$47.4M
TWST icon
12
Twist Bioscience
TWST
$5.97B
$45.3M 2.68%
1,000,000
– –
CDNA icon
13
CareDx
CDNA
$2.48B
$42.3M 2.5%
1,193,335
-101,000
-8% -$2.87M
RVMD icon
14
Revolution Medicines
RVMD
$38.8B
$42.1M 2.49%
1,334,536
+15,000
+1% +$472K
ADVM
15
DELISTED
Adverum Biotechnologies
ADVM
$38.9M 2.3%
186,500
+74,000
+66% +$13.1M
ADPT icon
16
Adaptive Biotechnologies
ADPT
$3.71B
$34.5M 2.04%
713,125
-80,000
-10% -$2.92M
GBIO
17
DELISTED
Generation Bio
GBIO
$33.8M 2%
+161,121
New +$35.9M
DNLI icon
18
Denali Therapeutics
DNLI
$3.67B
$31.7M 1.87%
1,310,000
-145,000
-10% -$3.41M
CNST
19
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$29.4M 1.74%
980,000
– –
ONC
20
BeOne Medicines Ltd
ONC
$32.3B
$28.3M 1.67%
+150,000
New +$24.4M
ALLO icon
21
Allogene Therapeutics
ALLO
$632M
$26.8M 1.58%
625,000
+125,000
+25% +$4.52M
FULC icon
22
Fulcrum Therapeutics
FULC
$280M
$26.4M 1.56%
1,441,176
+231,891
+19% +$3.65M
ALEC icon
23
Alector
ALEC
$168M
$26.3M 1.56%
1,076,039
– –
DNTH icon
24
Dianthus Therapeutics
DNTH
$5.72B
$25.1M 1.49%
209,127
+23,437
+13% +$3.3M
AMRS
25
DELISTED
Amyris Inc.
AMRS
$22.8M 1.35%
+5,349,376
New +$17.8M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Casdin Capital held 45 positions worth $1.69B, up 79% from $942M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Casdin Capital deployed $236M of net new capital in Q2 2020, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was Burning Rock Biotech: 173,079 shares worth $46.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 92% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $19.1M trimmed.

  • Casdin Capital's largest Q2 2020 buy was Burning Rock Biotech: 173,079 shares worth $46.7M.
  • Casdin Capital added most to Invitae Corporation in Q2 2020, an estimated $96.9M increase.
  • Casdin Capital's biggest Q2 2020 reduction was Sarepta Therapeutics, cutting an estimated $19.1M.
  • Casdin Capital fully exited GenMark Diagnostics, Inc in Q2 2020, selling an estimated $13.9M.
  • Casdin Capital's ten largest holdings make up 60% of its $1.69B portfolio in Q2 2020.
  • Casdin Capital opened 7 new positions and closed 3 in Q2 2020.
  • Casdin Capital's portfolio value rose 79% quarter-over-quarter to $1.69B.

Based on Casdin Capital's 13F filing for Q2 2020, filed 14 Aug 2020.